Lexeo Therapeutics (LXEO) reported positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia cardiomyopathy. In both the Lexeo-sponsored SUNRISE-FA Phase 1/2 clinical trial and the Weill Cornell Medicine investigator-initiated Phase 1A trial, treatment with LX2006 was associated with clinically significant improvements in cardiac biomarkers and functional measures, and increased frataxin protein expression was observed in all participants with cardiac biopsies.
"We believe these data show LX2006 exceeding the thresholds aligned with the U.S. Food and Drug Administration to support accelerated approval in the planned registrational study, said Sandi See Tai, Chief Development Officer at Lexeo.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.